Expertise in
15
conditions

Dr. William Bradley

Obstetrics and Gynecology
Cancer Center-Froedtert West Bend Hospital
3200 Pleasant Valley Rd, 
West Bend, WI 
Offers Telehealth
Expertise in
15
conditions
Cancer Center-Froedtert West Bend Hospital
3200 Pleasant Valley Rd, 
West Bend, WI 

Overview

William Bradley is an Obstetrics and Gynecologist in West Bend, Wisconsin. Dr. Bradley is highly rated in 15 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, and Hysterectomy.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 26 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in WI

Hospital Affiliations

Froedtert Memorial Lutheran Hospital
St Josephs Community Hospital West Bend
Holy Family Memorial

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cancer Center-Froedtert West Bend Hospital
3200 Pleasant Valley Rd, West Bend, WI 53095
Other Locations
Clinical Cancer Center-Froedtert Hospital
8800 W Doyne Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Rucaparib, Bevacizumab, Atezolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Tremelimumab
Study Phase: Phase 2
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

41 Total Publications

MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer.
MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Denise Uyar
Obstetrics and Gynecology
Expertise in
8
conditions
Dr. Denise Uyar
Obstetrics and Gynecology

Cancer Center-Froedtert Menomonee Falls Hospital

W180N8085 Town Hall Rd, 
Menomonee Falls, WI 
 (13.6 miles away)
262-251-1000
Languages Spoken:
English
See accepted insurances

Denise Uyar is an Obstetrics and Gynecologist in Menomonee Falls, Wisconsin. Dr. Uyar is highly rated in 8 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, and Hysterectomy.

Expertise in
14
conditions
Dr. Emily Hill
Obstetrics and Gynecology
Expertise in
14
conditions
Dr. Emily Hill
Obstetrics and Gynecology

Cancer Center-Drexel Town Square Health Center

7901 S 6th St, 
Oak Creek, WI 
 (34.3 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances

Emily Hill is an Obstetrics and Gynecologist in Oak Creek, Wisconsin. Dr. Hill is highly rated in 14 conditions, according to our data. Her top areas of expertise are Vulvar Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Hernia Surgery.

Tracy L. Capes
Expertise in
4
conditions
Dr. Tracy L. Capes
Obstetrics and Gynecology
Expertise in
4
conditions
Dr. Tracy L. Capes
Obstetrics and Gynecology

Center For Continence & Pelvic Floor Disorders

8901 W Lincoln Ave, Ste 405, 
West Allis, WI 
 (25.9 miles away)
414-329-5650
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Tracy Capes is an Obstetrics and Gynecologist in West Allis, Wisconsin. Dr. Capes is highly rated in 4 conditions, according to our data. Her top areas of expertise are Uterine Prolapse, Urinary Incontinence, Stress Urinary Incontinence, and Rectocele.

Frequently Asked Questions about Dr. William Bradley

How do I make an appointment with Dr. William Bradley?

You can book an appointment with Dr. William Bradley by calling their office at 262-836-7200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William Bradley a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William Bradley is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William Bradley specialize in?

While Dr. William Bradley is a Obstetrics and Gynecology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. William Bradley participate in research or clinical trials?

Yes. Dr. William Bradley has published 41 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. William Bradley's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. William Bradley accept my insurance?

Dr. William Bradley accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 262-836-7200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bradley's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile